Exagen (FRA:E08A) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E08A Exagen Inc FRA:E08A
62 GF Score
Price €4.28
GF Value €2.74
! 3 Warning Signs
View Full Analysis

What is Exagen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:E08A vs BNR, IMDX, IDXG: Short Interest Comparison

For the Diagnostics & Research subindustry, Exagen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exagen Short Interest vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's Short Interest distribution charts can be found below:

* The bar in red indicates where Exagen's Short Interest falls into.


FRA:E08A
62GF Score
Exagen Inc FRA:E08A
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exagen (FRA:E08A) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of €4.28 is trading 56.2% above its estimated GF Value™ of €2.74.

Key valuation signals for FRA:E08A:

  • Short Interest:
  • GF Value™: €2.74 vs. price of €4.28 (56.2% above fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the FRA:E08A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges XGN:USA
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
62GF Score

Get the complete analysis for FRA:E08A

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.28
Price
€2.74
GF Value